Drug Patents owned by Allergan
1. Drug name - ACULAR LS
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8008338 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2027
(4 years from now) | |
| EP3217937A4 | ALLERGAN | Bed Systems And Methods |
Nov, 2035
(13 years from now) | |
| EP3217937A1 | ALLERGAN | Bed Systems |
Nov, 2035
(13 years from now) | |
| EP3217937B1 | ALLERGAN | Bed Systems |
Nov, 2035
(13 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8946281 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(1 year, 7 months from now) | |
| US8906950 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(1 year, 7 months from now) | |
| US8648107 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(1 year, 7 months from now) | |
| US8541463 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(1 year, 7 months from now) | |
| US9216167 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(1 year, 7 months from now) | |
| US8377982 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(1 year, 7 months from now) | |
| US8207215 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(1 year, 7 months from now) | |
|
US8541463
(Pediatric) | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2024
(2 years from now) | |
|
US8207215
(Pediatric) | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2024
(2 years from now) | |
|
US8377982
(Pediatric) | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2024
(2 years from now) | |
|
US8008338
(Pediatric) | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2027
(5 years from now) | |
Drugs and Companies using KETOROLAC TROMETHAMINE ingredient
Treatment: A method of treating ocular pain; A method of treating or preventing ocular pain and burning; A method of treating or reducing ocular pain and burning/stinging; A method of treating ocular pain and/or enhancing ocular comfort; A method of treating or preventing ocular pain and burning/stinging following corneal surgery; A method of controlling postoperative ocular pain and burning/stinging in a patient
Dosage: SOLUTION/DROPS;OPHTHALMIC
| Strength | Dosage | Availability |
|---|---|---|
| 0.4% | SOLUTION/DROPS;OPHTHALMIC | Prescription |
2. Drug name - ACUVAIL
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7842714 | ALLERGAN | Ketorolac tromethamine compositions for treating ocular pain |
Aug, 2029
(6 years from now) | |
| CN102014869A | ALLERGAN | Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain |
Sep, 2015
(7 years ago) | |
| CN103976943A | ALLERGAN | Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain |
Mar, 2029
(6 years from now) | |
| CN103976943B | ALLERGAN | Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain |
Mar, 2029
(6 years from now) | |
| CN102497856A | ALLERGAN | Ketorolac Tromethamine Composition For Treating Or Preventing Eye Pain |
Aug, 2030
(7 years from now) | |
| CN102497856B | ALLERGAN | For Treating Or Prevention Eye Pain Of Ketorolac Tromethamine Composition |
Aug, 2030
(7 years from now) | |
| IN201006461P1 | ALLERGAN | Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain |
Mar, 2029
(6 years from now) | |
| IN286644B | ALLERGAN | Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain |
Mar, 2029
(6 years from now) | |
| EP2257275A2 | ALLERGAN | Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain |
Mar, 2029
(6 years from now) | |
| EP2446878A1 | ALLERGAN | Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain |
Mar, 2029
(6 years from now) | |
| EP2257275B1 | ALLERGAN | Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain |
Mar, 2029
(6 years from now) | |
| EP2446878B1 | ALLERGAN | Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain |
Mar, 2029
(6 years from now) | |
| EP2473157B1 | ALLERGAN | Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain |
Aug, 2030
(7 years from now) | |
| EP2473157A1 | ALLERGAN | Ketorolac Tromethamine Compositions For Treating Or Preventing Ocular Pain |
Aug, 2030
(7 years from now) | |
| EP2555770B1 | ALLERGAN | Ketorolac Compositions For Corneal Wound Healing |
Apr, 2031
(8 years from now) | |
| EP2555770A1 | ALLERGAN | Ketorolac Compositions For Corneal Wound Healing |
Apr, 2031
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8992952 | ALLERGAN | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
Aug, 2024
(1 year, 10 months from now) | |
| US8512717 | ALLERGAN | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
Mar, 2028
(5 years from now) | |
| US9192571 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Mar, 2028
(5 years from now) | |
Drugs and Companies using KETOROLAC TROMETHAMINE ingredient
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
| Strength | Dosage | Availability |
|---|---|---|
| 0.45% | SOLUTION/DROPS;OPHTHALMIC | Prescription |
3. Drug name - ALPHAGAN P
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8858961 | ALLERGAN | Compositions containing alpha-2-adrenergic agonist components |
Sep, 2023
(11 months from now) | |
|
US8858961
(Pediatric) | ALLERGAN | Compositions containing alpha-2-adrenergic agonist components |
Mar, 2024
(1 year, 5 months from now) | |
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
| Strength | Dosage | Availability |
|---|---|---|
| 0.1% | SOLUTION/DROPS;OPHTHALMIC | Prescription |
4. Drug name - AVYCAZ
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7112592 | ALLERGAN | Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents |
Jan, 2026
(3 years from now) | |
| US8471025 | ALLERGAN | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt |
Aug, 2031
(8 years from now) | |
| US8969566 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(9 years from now) | |
| US9695122 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(9 years from now) | |
| US9284314 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(9 years from now) | |
| CN104592229A | ALLERGAN | Polymorphic Form And False Polymorphic Form Of Medicine Composition |
Aug, 2019
(3 years ago) | |
| CN1289500C | ALLERGAN | Nitrogen Heterocyclic Ring Compounds, Their Preparation Method And Their Application As Medicine, Especially Application As Antibacterial Agent |
Jul, 2021
(1 year, 2 months ago) | |
| CN1468242A | ALLERGAN | Nitrogen Heterocyclic Ring Compounds, Their Preparation Method And Their Application As Medicine, Especially Application As Antibacterial Agent |
Jul, 2021
(1 year, 2 months ago) | |
| CN102834395B | ALLERGAN | Polymorphic Form And False Polymorphic Form Of Medicine Composition |
Oct, 2030
(8 years from now) | |
| CN102834395A | ALLERGAN | Polymorphic Form And False Polymorphic Form Of Medicine Composition |
Oct, 2030
(8 years from now) | |
| CN105294690A | ALLERGAN | The Preparation Comprises -7 - Oxo -6-(Sulfo-Oxy) -1, 6-Diazabicyclo [3 2 1] Octane - -2 - Formamide Heterocyclic Compound And Salt Thereof |
Jun, 2032
(9 years from now) | |
| CN103649051A | ALLERGAN | Method For Preparing Heterocyclic Compound Comprising Reverse-7-Oxo- -6-(Sulfo Group) -1, 6-Two [3, 2, 1] -2 -Carboxamide And The Salt Thereof |
Jun, 2032
(9 years from now) | |
| CN105294690B | ALLERGAN | Preparation Comprising Anti - -7 - Oxo - -6-(Sulfo Group) -1, 6-Di-Aza-Bicyclo (3, 2, 1] -2 - Formamide Heterocyclic Compound And Its Salt Method |
Jun, 2032
(9 years from now) | |
| CN103649051B | ALLERGAN | Method For Preparing Heterocyclic Compound Comprising Reverse-7-Oxo- -6-(Sulfo Group) -1, 6-Two [3, 2, 1] -2 -Carboxamide And The Salt Thereof |
Jun, 2032
(9 years from now) | |
| IN248632B | ALLERGAN | Azabicyclic Heterocyclic Compound |
Jul, 2021
(1 year, 2 months ago) | |
| IN238630B | ALLERGAN | Process For The Preparation Of A Heterocyclic Compound |
Jul, 2021
(1 year, 2 months ago) | |
| IN200503239P1 | ALLERGAN | Compound Of General Formula (I) Or One Its Salts With A Base Or An Acid |
Jul, 2021
(1 year, 2 months ago) | |
| IN200300268P1 | ALLERGAN | Azabicyclic Compounds, Preparation Thereof And Use As Medicines, In Particular As Antibacterial Agents |
Jul, 2021
(1 year, 2 months ago) | |
| EP1307457B1 | ALLERGAN | Azabicyclic Compounds, Preparation Thereof And Use As Medicines, In Particular As Antibacterial Agents |
Jul, 2021
(1 year, 2 months ago) | |
| EP1307457A1 | ALLERGAN | Azabicyclic Compounds, Preparation Thereof And Use As Medicines, In Particular As Antibacterial Agents |
Jul, 2021
(1 year, 2 months ago) | |
| EP3269717A1 | ALLERGAN | Polymorphic And Pseudopolymorphic Forms Of Pharmaceutical Compound Nxl104 |
Oct, 2030
(8 years from now) | |
| EP3269717B1 | ALLERGAN | Polymorphic And Pseudopolymorphic Forms Of Pharmaceutical Compound Nxl104 |
Oct, 2030
(8 years from now) | |
| EP2486038B1 | ALLERGAN | Polymorphic And Pseudopolymorphic Forms Of A Pharmaceutical Compound |
Oct, 2030
(8 years from now) | |
| EP2486038A1 | ALLERGAN | Polymorphic And Pseudopolymorphic Forms Of A Pharmaceutical Compound |
Oct, 2030
(8 years from now) | |
| EP2721005B1 | ALLERGAN | Process For Preparing Heterocyclic Compounds Including Trans-7-Oxo-6-(Sulphooxy)-1,6-Diazabicyclo[3,2,1]Octane-2-Carboxamide And Salts Thereof |
Jun, 2032
(9 years from now) | |
| EP2721005A1 | ALLERGAN | Process For Preparing Heterocyclic Compounds Including Trans-7-Oxo-6-(Sulphooxy)-1,6-Diazabicyclo[3,2,1]Octane-2-Carboxamide And Salts Thereof |
Jun, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7612087 | ALLERGAN | Heterocyclic compounds as inhibitors of beta-lactamases |
Nov, 2026
(4 years from now) | |
| US8835455 | ALLERGAN | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt |
Oct, 2030
(8 years from now) | |
Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient
Treatment: NA
Dosage: POWDER;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| EQ 0.5GM BASE;2GM/VIAL | POWDER;INTRAVENOUS | Prescription |
5. Drug name - BYVALSON
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7803838 | ALLERGAN | Compositions comprising nebivolol |
Aug, 2026
(3 years from now) | |
| US7838552 | ALLERGAN | Compositions comprising nebivolol |
Oct, 2027
(5 years from now) | |
Drugs and Companies using NEBIVOLOL HYDROCHLORIDE; VALSARTAN ingredient
Treatment: Method of treating hypertension
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 5MG BASE;80MG | TABLET;ORAL | Discontinued |
6. Drug name - CANASA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8217083 | ALLERGAN | Mesalamine suppository |
Jun, 2028
(5 years from now) | |
| US8436051 | ALLERGAN | Mesalamine suppository |
Jun, 2028
(5 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 1GM | SUPPOSITORY;RECTAL | Prescription |
| 500MG | SUPPOSITORY;RECTAL | Discontinued |
7. Drug name - COMBIGAN
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7642258 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(5 months ago) | |
| CN101664414A | ALLERGAN | Combination Of Brimonidine And Timolol For Topical Ophthalmic Use |
Jan, 2013
(9 years ago) | |
| CN112219061A | ALLERGAN | Suspension Type Vertical Decoration Light Guide Lamp With Sound Suppression |
Jan, 2022
(8 months ago) | |
| CN1516588A | ALLERGAN | Combination Of Brimonidine And Timolol For Topical Ophthalmic Use |
Apr, 2023
(6 months from now) | |
| CN100558364C | ALLERGAN | Combination Of Brimonidine And Timolol For Topical Ophthalmic Use |
Apr, 2023
(6 months from now) | |
| EP1496912B1 | ALLERGAN | Combination Of Brimonidine And Timolol For Topical Ophthalmic Use |
Apr, 2023
(6 months from now) | |
| EP1496912A1 | ALLERGAN | Combination Of Brimonidine And Timolol For Topical Ophthalmic Use |
Apr, 2023
(6 months from now) | |
| EP1496912B9 | ALLERGAN | Combination Of Brimonidine And Timolol For Topical Ophthalmic Use |
Apr, 2023
(6 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7323463 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Jan, 2023
(3 months from now) | |
Drugs and Companies using BRIMONIDINE TARTRATE; TIMOLOL MALEATE ingredient
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
| Strength | Dosage | Availability |
|---|---|---|
| 0.2%;EQ 0.5% BASE | SOLUTION/DROPS;OPHTHALMIC | Prescription |
8. Drug name - DALVANCE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7115564 | ALLERGAN | Stable pharmaceutical compositions of dalbavancin and methods of administration |
Nov, 2023
(1 year, 1 month from now) | |
| US8143212 | ALLERGAN | Dalbavancin compositions for treatment of bacterial infections |
Nov, 2023
(1 year, 1 month from now) | |
| US7119061 | ALLERGAN | Dalbavancin compositions for treatment of bacterial infections |
Nov, 2023
(1 year, 1 month from now) | |
| US6900175 | ALLERGAN | Methods of administering dalbavancin for treatment of bacterial infections |
Dec, 2023
(1 year, 2 months from now) | |
Drugs and Companies using DALBAVANCIN HYDROCHLORIDE ingredient
Treatment: Treatment of bacterial infections using a two-dose regimen of dalbavancin.
Dosage: POWDER;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| EQ 500MG BASE/VIAL | POWDER;INTRAVENOUS | Prescription |
9. Drug name - FETZIMA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8865937 | ALLERGAN | Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide |
May, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE43879 | ALLERGAN | Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug |
Jan, 2026
(3 years from now) | |
| US8481598 | ALLERGAN | Stable dosage forms of levomilnacipran |
Mar, 2031
(8 years from now) | |
Drugs and Companies using LEVOMILNACIPRAN HYDROCHLORIDE ingredient
Treatment: Treatment of major depressive disorder (mdd)
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 20MG BASE | CAPSULE, EXTENDED RELEASE;ORAL | Prescription |
| EQ 40MG BASE | CAPSULE, EXTENDED RELEASE;ORAL | Prescription |
| EQ 80MG BASE | CAPSULE, EXTENDED RELEASE;ORAL | Prescription |
| EQ 120MG BASE | CAPSULE, EXTENDED RELEASE;ORAL | Prescription |
10. Drug name - GELNIQUE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9259388 | ALLERGAN | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
Nov, 2029
(7 years from now) | |
| US10449173 | ALLERGAN | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
Nov, 2029
(7 years from now) | |
| US8920392 | ALLERGAN | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
Mar, 2031
(8 years from now) | |
Drugs and Companies using OXYBUTYNIN CHLORIDE ingredient
Treatment: Treatment of overactive bladder by application of oxybutynin chloride gel to skin; Treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence with a single unit dose of 10% oxybutynin chloride gel
Dosage: GEL;TRANSDERMAL
| Strength | Dosage | Availability |
|---|---|---|
| 10% (100MG/PACKET) | GEL;TRANSDERMAL | Prescription |
11. Drug name - LASTACAFT
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10617695 | ALLERGAN | Ophthalmic compositions containing alcaftadine |
Mar, 2027
(4 years from now) | |
| US8664215 | ALLERGAN | Ocular allergy treatments with alcaftadine |
Dec, 2027
(5 years from now) | |
Drugs and Companies using ALCAFTADINE ingredient
Treatment: Use of lastacaft to temporary relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander
Dosage: SOLUTION/DROPS;OPHTHALMIC
| Strength | Dosage | Availability |
|---|---|---|
| 0.25% | SOLUTION/DROPS;OPHTHALMIC | Over the counter |
12. Drug name - LATISSE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8038988 | ALLERGAN | Method of enhancing hair growth |
Aug, 2023
(10 months from now) | |
| EP2802331A1 | ALLERGAN | Topical Treatment For Chemotherapy Induced Eyelash Loss Or Hypotrichosis Using Prostamide F2 Alpha Agonists |
Jan, 2033
(10 years from now) | |
| EP2802331B1 | ALLERGAN | Topical Treatment For Chemotherapy Induced Eyelash Loss Or Hypotrichosis Using Prostamide F2 Alpha Agonists |
Jan, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8986715 | ALLERGAN | Method of enhancing hair growth |
Jan, 2023
(3 months from now) | |
| US8632760 | ALLERGAN | Method of enhancing hair growth |
Jan, 2023
(3 months from now) | |
| US9216183 | ALLERGAN | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan, 2023
(3 months from now) | |
| US8758733 | ALLERGAN | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan, 2023
(3 months from now) | |
| US9226931 | ALLERGAN | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan, 2023
(3 months from now) | |
| US8263054 | ALLERGAN | Method of enhancing hair growth |
Jan, 2023
(3 months from now) | |
| US8101161 | ALLERGAN | Method of enhancing hair growth |
May, 2024
(1 year, 7 months from now) | |
Drugs and Companies using BIMATOPROST ingredient
Treatment: Method of increasing hair growth; Method of increasing eyelash growth; Method of increasing growth of hair including eyelashes; Method of increasing eyelash growth including length, thickness, darkness and/or number of eyelashes by administering bimatoprost to an eyelid margin; Method of stimulating hair growth; method of increasing hair growth
Dosage: SOLUTION/DROPS;TOPICAL
| Strength | Dosage | Availability |
|---|---|---|
| 0.03% | SOLUTION/DROPS;TOPICAL | Prescription |
13. Drug name - LEXAPRO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6916941 | ALLERGAN | Crystalline composition containing escitalopram |
Aug, 2022
(a month ago) | |
| CN1660074A | ALLERGAN | Crystalline Composition Containing Escitalopram |
Oct, 2007
(15 years ago) | |
| CN1311819C | ALLERGAN | Crystalline Composition Containing Escitalopram |
Jul, 2022
(2 months ago) | |
| CN1536997A | ALLERGAN | Crystalline Composition Containing Escitalopram |
Jul, 2022
(2 months ago) | |
| IN227935B | ALLERGAN | A Method For Manufacture Of Crystalline Particles Of Escitalpram Oxalate |
Jul, 2022
(2 months ago) | |
| IN200400405P4 | ALLERGAN | Crystalline Composition Containing Escitalopram |
Jul, 2022
(2 months ago) | |
| EP1522539A1 | ALLERGAN | Crystalline Composition Containing Escitalopram |
Sep, 2010
(12 years ago) | |
| EP1522539B1 | ALLERGAN | Crystalline Composition Containing Escitalopram |
Sep, 2010
(12 years ago) | |
| EP1414435B1 | ALLERGAN | Crystalline Composition Containing Escitalopram |
Jul, 2022
(2 months ago) | |
| EP1414435A1 | ALLERGAN | Crystalline Composition Containing Escitalopram |
Jul, 2022
(2 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6916941
(Pediatric) | ALLERGAN | Crystalline composition containing escitalopram |
Feb, 2023
(4 months from now) | |
|
US7420069
(Pediatric) | ALLERGAN | Crystalline composition containing escitalopram |
Feb, 2023
(4 months from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| EQ 5MG BASE | TABLET;ORAL | Prescription |
| EQ 10MG BASE | TABLET;ORAL | Prescription |
| EQ 20MG BASE | TABLET;ORAL | Prescription |
14. Drug name - LINZESS
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7704947 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 3 months from now) | |
| US8080526 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 3 months from now) | |
| US7371727 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 3 months from now) | |
| US7745409 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 3 months from now) | |
| US7304036 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Aug, 2026
(3 years from now) | |
| CN101010335A | ALLERGAN | The Method And Combination For Curing The Gastrointestinal Disease |
Sep, 2011
(11 years ago) | |
| CN102020704A | ALLERGAN | Method And Composition For The Treatment Of Gastrointestinal Disorders |
Apr, 2013
(9 years ago) | |
| CN101787073A | ALLERGAN | Method And Composition For The Treatment Of Gastrointestinal Disorders |
Jan, 2024
(1 year, 3 months from now) | |
| CN101787073B | ALLERGAN | Methods And Compositions For The Treatment Of Gastrointestinal Disorders |
Jan, 2024
(1 year, 3 months from now) | |
| CN1795007A | ALLERGAN | Method And Composition For The Treatment Of Gastrointestinal Disorders |
Jan, 2024
(1 year, 3 months from now) | |
| CN100589839C | ALLERGAN | Polypeptide And A Pharmaceutical Composition Comprising The Polypeptide |
Jan, 2024
(1 year, 3 months from now) | |
| IN200503394P1 | ALLERGAN | Methods And Compositions For The Treatment Of Gastrointestinal Disorders |
Jan, 2024
(1 year, 3 months from now) | |
| IN237521B | ALLERGAN | A Purified Peptide Which Activates The Guanylate Cyclase C Receptor For Use In Gastrointestinal Disorders |
Jan, 2024
(1 year, 3 months from now) | |
| EP1911763B1 | ALLERGAN | Compositions For The Treatment Of Gastrointestinal Disorders |
Jan, 2024
(1 year, 3 months from now) | |
| EP1911763A2 | ALLERGAN | Compositions For The Treatment Of Gastrointestinal Disorders |
Jan, 2024
(1 year, 3 months from now) | |
| EP1911763A3 | ALLERGAN | Compositions For The Treatment Of Gastrointestinal Disorders |
Jan, 2024
(1 year, 3 months from now) | |
| EP2088154B1 | ALLERGAN | Methods And Compositions For The Treatment Of Gastrointestinal Disorders |
Mar, 2025
(2 years from now) | |
| EP2088154A1 | ALLERGAN | Methods And Compositions For The Treatment Of Gastrointestinal Disorders |
Mar, 2025
(2 years from now) | |
| EP2246360A1 | ALLERGAN | Compositions For The Treatment Of Gastrointestinal Disorders |
Nov, 2027
(5 years from now) | |
| EP2246360B1 | ALLERGAN | Compositions For The Treatment Of Gastrointestinal Disorders |
Nov, 2027
(5 years from now) | |
| EP1594517A4 | ALLERGAN | Methods And Compositions For The Treatment Of Gastrointestinal Disorders |
Nov, 2027
(5 years from now) | |
| EP1594517B1 | ALLERGAN | Compositions For The Treatment Of Gastrointestinal Disorders |
Nov, 2027
(5 years from now) | |
| EP1594517A2 | ALLERGAN | Compositions For The Treatment Of Gastrointestinal Disorders |
Nov, 2027
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8110553 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 3 months from now) | |
| US8933030 | ALLERGAN | Treatments for gastrointestinal disorders |
Feb, 2031
(8 years from now) | |
| US10702576 | ALLERGAN | Stable formulations of linaclotide |
Aug, 2031
(8 years from now) | |
| US10675325 | ALLERGAN | Stable formulations of linaclotide |
Aug, 2031
(8 years from now) | |
| US8748573 | ALLERGAN | Formulations comprising linaclotide |
Oct, 2031
(9 years from now) | |
| US8802628 | ALLERGAN | Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration |
Oct, 2031
(9 years from now) | |
| US9708371 | ALLERGAN | Treatments for gastrointestinal disorders |
Aug, 2033
(10 years from now) | |
Drugs and Companies using LINACLOTIDE ingredient
Treatment: Method of treating chronic idiopathic constipation in adult patients.; method of treating irritable bowel syndrome with constipation in adults; Method of treating chronic idiopathic constipation in adult patients.; Method of treating chronic idiopathic constipation in adult patients.; method of treating irritable bowel syndrome with constipation in adult patients.; Method of treating irritable bowel syndrome with constipation in adult patients.; method of treating chronic idiopathic constipation in adult patients.
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 72MCG | CAPSULE;ORAL | Prescription |
| 145MCG | CAPSULE;ORAL | Prescription |
| 290MCG | CAPSULE;ORAL | Prescription |
15. Drug name - LUMIGAN
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7851504 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Jun, 2027
(4 years from now) | |
| CN101137383A | ALLERGAN | Enhanced Bimatoprost Ophthalmic Solution |
Mar, 2026
(3 years from now) | |
| CN102240292A | ALLERGAN | Enhanced Bimatoprost Ophthalmic Solution |
Mar, 2026
(3 years from now) | |
| CN101137383B | ALLERGAN | Enhanced Bimatoprost Ophthalmic Solution |
Mar, 2026
(3 years from now) | |
| CN102240292B | ALLERGAN | Enhanced Bimatoprost Ophthalmic Solution |
Mar, 2026
(3 years from now) | |
| IN263623B | ALLERGAN | Enhanced Bimatoprost Ophthalmic Solution |
Mar, 2026
(3 years from now) | |
| IN200706652P1 | ALLERGAN | Enhanced Bimatoprost Opthalmic Solution |
Mar, 2026
(3 years from now) | |
| EP1753434A2 | ALLERGAN | Enhanced Bimatoprost Ophthalmic Solution |
Mar, 2026
(3 years from now) | |
| EP1753434B1 | ALLERGAN | Enhanced Bimatoprost Ophthalmic Solution |
Mar, 2026
(3 years from now) | |
| EP1753434B2 | ALLERGAN | Enhanced Bimatoprost Ophthalmic Solution |
Mar, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9155716 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
| US8524777 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
| US8338479 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
| US8772338 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
| US8299118 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
| US9241918 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
| US8933120 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
| US8933127 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
| US8278353 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
| US8309605 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
| US8586630 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
Drugs and Companies using BIMATOPROST ingredient
Treatment: A method of lowering intraocular pressure; Reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension; A method of treating a patient with glaucoma or ocular hypertension; Method of treating glaucoma or elevated intraocular pressure; A method of lowering intraocular pressure in a patient with open angle glaucoma or ocular hypertension; method of treating glaucoma in a patient; A method of reducing intraocular pressure in patients with open angle glaucoma or ocular hypertension
Dosage: SOLUTION/DROPS;OPHTHALMIC
| Strength | Dosage | Availability |
|---|---|---|
| 0.01% | SOLUTION/DROPS;OPHTHALMIC | Prescription |
16. Drug name - NAMENDA XR
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8039009 | ALLERGAN | Modified release formulations of memantine oral dosage forms |
Mar, 2029
(6 years from now) | |
|
US8039009
(Pediatric) | ALLERGAN | Modified release formulations of memantine oral dosage forms |
Sep, 2029
(6 years from now) | |
Drugs and Companies using MEMANTINE HYDROCHLORIDE ingredient
Treatment: Treatment of moderate to severe dementia of the alzheimer's type
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 7MG | CAPSULE, EXTENDED RELEASE;ORAL | Prescription |
| 14MG | CAPSULE, EXTENDED RELEASE;ORAL | Prescription |
| 21MG | CAPSULE, EXTENDED RELEASE;ORAL | Prescription |
| 28MG | CAPSULE, EXTENDED RELEASE;ORAL | Prescription |
17. Drug name - NAMZARIC
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8580858 | ALLERGAN | Compositions for the treatment of CNS-related conditions |
Nov, 2025
(3 years from now) | |
| US8168209 | ALLERGAN | Method and composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(3 years from now) | |
| US8598233 | ALLERGAN | Method for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(3 years from now) | |
| US8338485 | ALLERGAN | Compositions for the treatment of CNS-related conditions |
Nov, 2025
(3 years from now) | |
| US8173708 | ALLERGAN | Method and composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(3 years from now) | |
| US8362085 | ALLERGAN | Method for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(3 years from now) | |
| US8293794 | ALLERGAN | Methods and compositions for the treatment of CNS-related conditions |
Nov, 2025
(3 years from now) | |
| US8338486 | ALLERGAN | Methods for the treatment of CNS-related conditions |
Nov, 2025
(3 years from now) | |
| US8283379 | ALLERGAN | Methods and compositions for the treatment of CNS-related conditions |
Nov, 2025
(3 years from now) | |
| US8329752 | ALLERGAN | Composition for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(3 years from now) | |
|
US8598233
(Pediatric) | ALLERGAN | Method for administering an NMDA receptor antagonist to a subject |
May, 2026
(3 years from now) | |
|
US8362085
(Pediatric) | ALLERGAN | Method for administering an NMDA receptor antagonist to a subject |
May, 2026
(3 years from now) | |
|
US8173708
(Pediatric) | ALLERGAN | Method and composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(3 years from now) | |
|
US8168209
(Pediatric) | ALLERGAN | Method and composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(3 years from now) | |
|
US8283379
(Pediatric) | ALLERGAN | Methods and compositions for the treatment of CNS-related conditions |
May, 2026
(3 years from now) | |
|
US8329752
(Pediatric) | ALLERGAN | Composition for administering an NMDA receptor antagonist to a subject |
May, 2026
(3 years from now) | |
| US8039009 | ALLERGAN | Modified release formulations of memantine oral dosage forms |
Mar, 2029
(6 years from now) | |
|
US8039009
(Pediatric) | ALLERGAN | Modified release formulations of memantine oral dosage forms |
Sep, 2029
(6 years from now) | |
| US8058291 | ALLERGAN | Methods and compositions for the treatment of CNS-related conditions |
Dec, 2029
(7 years from now) | |
Drugs and Companies using DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE ingredient
Treatment: Memantine hcl/donepezil hcl combination for the treatment of moderate to severe dementia of the alzheimer's type
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 10MG;7MG | CAPSULE, EXTENDED RELEASE;ORAL | Prescription |
| 10MG;14MG | CAPSULE, EXTENDED RELEASE;ORAL | Prescription |
| 10MG;21MG | CAPSULE, EXTENDED RELEASE;ORAL | Prescription |
| 10MG;28MG | CAPSULE, EXTENDED RELEASE;ORAL | Prescription |
18. Drug name - OZURDEX
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10702539 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(3 months from now) | |
| US8506987 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(3 months from now) | |
| US8034366 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(3 months from now) | |
| US8034370 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(3 months from now) | |
| US10076526 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(3 months from now) | |
| US9192511 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(3 months from now) | |
| US6899717 | ALLERGAN | Methods and apparatus for delivery of ocular implants |
Nov, 2023
(1 year, 1 month from now) | |
Drugs and Companies using DEXAMETHASONE ingredient
Treatment: Treatment of diabetic macular edema; treatment of macular edema following branch retinal vein occlusion (brvo) or central retinal vein occlusion (crvo); treatment of non-infectious uveitis affecting the posterior segment of the eye; Treatment of macular edema; treatment of uveitis; Delivering an ocular implant as described in the dosage and administration section of the approved labeling of ozurdex
Dosage: IMPLANT;INTRAVITREAL
| Strength | Dosage | Availability |
|---|---|---|
| 0.7MG | IMPLANT;INTRAVITREAL | Prescription |
19. Drug name - RESTASIS
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9248191 | ALLERGAN | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(1 year, 10 months from now) | |
| US8633162 | ALLERGAN | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(1 year, 10 months from now) | |
| US8629111 | ALLERGAN | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(1 year, 10 months from now) | |
| US8648048 | ALLERGAN | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(1 year, 10 months from now) | |
| US8642556 | ALLERGAN | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(1 year, 10 months from now) | |
| US8685930 | ALLERGAN | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(1 year, 10 months from now) | |
| US8292129 | ALLERGAN | Dispensing device |
Feb, 2031
(8 years from now) | |
| US8561859 | ALLERGAN | Dispensing device |
Apr, 2032
(9 years from now) | |
| US9676525 | ALLERGAN | Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids |
Feb, 2034
(11 years from now) | |
| US9669974 | ALLERGAN | Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids |
May, 2034
(11 years from now) | |
Drugs and Companies using CYCLOSPORINE ingredient
Treatment: Increase tear production to treat patients with keratoconjunctivitis sicca (dry eye).; Increase tear production in patients with keratoconjunctivitis sicca (dry eye).
Dosage: EMULSION;OPHTHALMIC
| Strength | Dosage | Availability |
|---|---|---|
| 0.05% | EMULSION;OPHTHALMIC | Prescription |
20. Drug name - SAPHRIS
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7741358 | ALLERGAN | Crystal form of asenapine maleate |
Apr, 2026
(3 years from now) | |
| US8022228 | ALLERGAN | Crystal form of asenapine maleate |
Apr, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8022228
(Pediatric) | ALLERGAN | Crystal form of asenapine maleate |
Oct, 2026
(4 years from now) | |
|
US7741358
(Pediatric) | ALLERGAN | Crystal form of asenapine maleate |
Oct, 2026
(4 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| EQ 2.5MG BASE | TABLET;SUBLINGUAL | Prescription |
| EQ 5MG BASE | TABLET;SUBLINGUAL | Prescription |
| EQ 10MG BASE | TABLET;SUBLINGUAL | Prescription |
21. Drug name - SAVELLA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6602911 | ALLERGAN | Methods of treating fibromyalgia |
Jan, 2023
(3 months from now) | |
| US7994220 | ALLERGAN | Milnacipran for the long-term treatment of fibromyalgia syndrome |
Sep, 2029
(6 years from now) | |
Drugs and Companies using MILNACIPRAN HYDROCHLORIDE ingredient
Treatment: Management of fibromyalgia (fm); Management of fibromyalgia
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 12.5MG | TABLET;ORAL | Prescription |
| 25MG | TABLET;ORAL | Prescription |
| 50MG | TABLET;ORAL | Prescription |
| 100MG | TABLET;ORAL | Prescription |
22. Drug name - TEFLARO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6417175 | ALLERGAN | Phosphonocephem derivatives, process for the preparation of the same, and use thereof |
Apr, 2022
(5 months ago) | |
| CN1194980C | ALLERGAN | Phosphoryl Derivatives, Their Preparation And Use |
Dec, 2018
(3 years ago) | |
| CN1679595B | ALLERGAN | Phosphonoalkane Derivatives, Their Preparation And Use |
Dec, 2018
(3 years ago) | |
| CN1282335A | ALLERGAN | Phosphoryl Derivatives, Their Preparation And Use |
Dec, 2018
(3 years ago) | |
| CN1679595A | ALLERGAN | Phosphoryl Derivatives, Their Preparation And Use |
Dec, 2018
(3 years ago) | |
| EP1043327A4 | ALLERGAN | Phosphonocephem Derivatives, Process For The Preparation Of The Same, And Use Thereof |
Dec, 2023
(1 year, 2 months from now) | |
| EP1043327A1 | ALLERGAN | Phosphonocephem Derivatives, Process For The Preparation Of The Same, And Use Thereof |
Dec, 2023
(1 year, 2 months from now) | |
| EP1043327B1 | ALLERGAN | Phosphonocephem Derivatives, Process For The Preparation Of The Same, And Use Thereof |
Dec, 2023
(1 year, 2 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9629861 | ALLERGAN | Compositions and methods for treating bacterial infections using ceftaroline |
Sep, 2030
(7 years from now) | |
| US8247400 | ALLERGAN | Cephem compounds useful for the treatment of bacterial infections |
Feb, 2031
(8 years from now) | |
Drugs and Companies using CEFTAROLINE FOSAMIL ingredient
Treatment: Method of treating bacterial infections
Dosage: POWDER;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| 400MG/VIAL | POWDER;INTRAVENOUS | Prescription |
| 600MG/VIAL | POWDER;INTRAVENOUS | Prescription |
23. Drug name - UBRELVY
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9499545 | ALLERGAN | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(9 years from now) | |
| US8912210 | ALLERGAN | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(9 years from now) | |
| US8754096 | ALLERGAN | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Jul, 2032
(9 years from now) | |
| CN103328478A | ALLERGAN | Piperidones Carboxamide Indane Cgrp Receptor Antagonist |
Nov, 2031
(9 years from now) | |
| CN103328478B | ALLERGAN | Piperidone Carboxamide Nitrogen Mixed Indene Into Cgrp Receptor Antagonists |
Nov, 2031
(9 years from now) | |
| IN201303390P4 | ALLERGAN | Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists |
Nov, 2031
(9 years from now) | |
| IN289826B | ALLERGAN | Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists |
Nov, 2031
(9 years from now) | |
| EP2638042A1 | ALLERGAN | Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists |
Nov, 2031
(9 years from now) | |
| EP2821407B1 | ALLERGAN | Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists |
Nov, 2031
(9 years from now) | |
| EP2821407A1 | ALLERGAN | Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists |
Nov, 2031
(9 years from now) | |
| EP2638042B1 | ALLERGAN | Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists |
Nov, 2031
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9833448 | ALLERGAN | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(9 years from now) | |
| US10117836 | ALLERGAN | Tablet formulation for CGRP active compounds |
Jan, 2035
(12 years from now) | |
Drugs and Companies using UBROGEPANT ingredient
Treatment: Acute treatment of migraine with or without aura in adults
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 50MG | TABLET;ORAL | Prescription |
| 100MG | TABLET;ORAL | Prescription |
24. Drug name - VIIBRYD
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7834020 | ALLERGAN | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun, 2022
(3 months ago) | |
| US8673921 | ALLERGAN | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun, 2022
(3 months ago) | |
| CN100384841C | ALLERGAN | 1 - [4 - (5-Cyanoindol-3-Group) Butyl] - 4 - (2-Carbamoyl-Benzofuran-5-Yl) - Piperazine Hydrochloride Polymorph |
Jun, 2022
(3 months ago) | |
| CN101139345A | ALLERGAN | Polymorphic Forms Of 1-4-(5-Cyanoindol-3-Group) Butyl-4-(2-Carbamoylbenzofuran-5-Group) Piperazine Hydrochloride |
Jun, 2022
(3 months ago) | |
| CN1516699A | ALLERGAN | 1 - [4 - (5-Cyanoindol-3-Group) Butyl] - 4 - (2-Carbamoyl-Benzofuran-5-Yl) - Piperazine Hydrochloride Polymorph |
Jun, 2022
(3 months ago) | |
| CN101139345B | ALLERGAN | 1 - [4 - (5-Indole-3-Yl) Butyl] - 4 - (2-Carbamoyl-Benzofuran-5-Yl) - Piperazine Hydrochloride Polymorph |
Jun, 2022
(3 months ago) | |
| EP1397357B1 | ALLERGAN | Polymorphic Forms Of 1-[4-(5-Cyanoindol-3-Yl)Butyl]-4-(2-Carbamoylbenzofuran-5-Yl)Piperazine Hydrochloride |
Jun, 2022
(3 months ago) | |
| EP1397357A2 | ALLERGAN | Polymorphic Forms Of 1-[4-(5-Cyanoindol-3-Yl)Butyl]-4-(2-Carbamoylbenzofuran-5-Yl)Piperazine Hydrochloride |
Jun, 2022
(3 months ago) | |
| EP1397357B9 | ALLERGAN | Polymorphic Forms Of 1-[4-(5-Cyanoindol-3-Yl)Butyl]-4-(2-Carbamoylbenzofuran-5-Yl)Piperazine Hydrochloride |
Jun, 2022
(3 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8236804
(Pediatric) | ALLERGAN | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
Dec, 2022
(2 months from now) | |
|
US8193195
(Pediatric) | ALLERGAN | Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(2 months from now) | |
|
US8673921
(Pediatric) | ALLERGAN | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(2 months from now) | |
|
US7834020
(Pediatric) | ALLERGAN | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Dec, 2022
(2 months from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 10MG | TABLET;ORAL | Prescription |
| 20MG | TABLET;ORAL | Prescription |
| 40MG | TABLET;ORAL | Prescription |
25. Drug name - VRAYLAR
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7943621 | ALLERGAN | Salts of piperazine compounds as D3/D2 antagonists |
Dec, 2028
(6 years from now) | |
| US7737142 | ALLERGAN | (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists |
Sep, 2029
(6 years from now) | |
| CN1829703B | ALLERGAN | As A D 3 /D 2 Receptor Antagonist (Thio) Carbamoyl-Cyclohexane Derivatives |
May, 2024
(1 year, 7 months from now) | |
| CN1829703A | ALLERGAN | As D |
May, 2024
(1 year, 7 months from now) | |
| CN101679315A | ALLERGAN | Novel Piperazine Salts As D3/D2 Antagonists |
May, 2028
(5 years from now) | |
| CN101679315B | ALLERGAN | A D <Sub> 3 </Sub> /D <Sub> 2 </Sub> A Piperazine Salt. |
May, 2028
(5 years from now) | |
| IN200904256P2 | ALLERGAN | Novel Piperazine Salts As D3/D2 Antagonists |
May, 2028
(5 years from now) | |
| IN293352B | ALLERGAN | A Process For The Preparation Of Novel Piperazine Salts As D3/D2 Antagonists |
May, 2028
(5 years from now) | |
| EP1663996B1 | ALLERGAN | (Thio)Carbamoyl-Cyclohexane Derivatives As D3/D2 Receptor Antagonists |
May, 2024
(1 year, 7 months from now) | |
| EP1663996A1 | ALLERGAN | (Thio)Carbamoyl-Cyclohexane Derivatives As D3/D2 Receptor Antagonists |
May, 2024
(1 year, 7 months from now) | |
| EP2155696A2 | ALLERGAN | Piperazine Salts As D3/D2 Antagonists |
May, 2028
(5 years from now) | |
| EP2155696B1 | ALLERGAN | Piperazine Salts As D3/D2 Antagonists |
May, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE47350 | ALLERGAN | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(6 years from now) | |
Drugs and Companies using CARIPRAZINE HYDROCHLORIDE ingredient
Treatment: Treatment of schizophrenia and/or acute manic or mixed episodes associated with bipolar i disorder with cariprazine; treatment of schizophrenia with cariprazine; treatment of acute manic or mixed episodes associated with bipolar i disorder with cariprazine; treatment of depressive episodes associated with bipolar i disorder (bipolar depression) with cariprazine
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 1.5MG BASE | CAPSULE;ORAL | Prescription |
| EQ 3MG BASE | CAPSULE;ORAL | Prescription |
| EQ 4.5MG BASE | CAPSULE;ORAL | Prescription |
| EQ 6MG BASE | CAPSULE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.